How many institutional investors hold GENB?

2 tracked institutional investors disclosed a position in GENB (GENERATE BIOMEDICINES INC) in their most recent 13F filing.

Who is the largest institutional holder of GENB?

Cathie Wood, ARK Investment Management, holds the largest disclosed position in GENB, valued at $22M.

Where does this GENB ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

GENB — GENERATE BIOMEDICINES INC

Name: GENERATE BIOMEDICINES INC (GENB) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying GENB?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence

Institutional Conviction

Strong distribution · 1 buying vs 2 selling last quarter

Macro Tailwind

Macro conditions are mixed for this sector

Why? — Evidence & Confidence ▾

Of 3 tracked investors who changed their GENB position last quarter, 1 bought and 2 sold (33% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence

+1 tracked investor added or increased positions last quarter (Cathie Wood)
+2 tracked investors reported holding GENB at their latest filing
+Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource

Contradicting evidence — always shown

−2 tracked investors reduced or exited last quarter (0 reduced, 2 sold out)
−13F data is disclosed up to 45 days after quarter end — positions may have changed since

Know the limits

· 13F disclosure lag (up to 45 days)
· Tracked investors are a sample, not the whole market
· Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About GENERATE BIOMEDICINES INC (GENB)

GENERATE BIOMEDICINES INC (GENB) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Cathie Wood (ARK Investment Management), valued at $22M. Across recent filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in GENB

/100

Institutional Accumulation

Added / Increased4

Reduced0

Exited2

BearishBullish

Crowded Trade Score™

How many top investors track GENB

/100

Undiscovered

2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded

151015+

GENB Ownership Composition

How GENERATE BIOMEDICINES INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Growth & Innovation

98% of tracked value

Institutions

tracked investors

Total Reported

$22M

combined 13F value

Growth & Innovation98.3%
Multi-Strategy / Quant1.7%

Growth & Innovation(1)

98.3%

Multi-Strategy / Quant(1)

1.7%

Tracked investors currently reporting GENB

1 tracked investor has since exited this position — listed separately below.

Investor	Firm	Shares	Market value	% of portfolio	As of
Cathie Wood	ARK Investment Management	1.3M	$21.7M	0.14%	Jun 30, 2026
Izzy Englander	Millennium Management	21.9K	$369.9K	0.00%	Jun 30, 2026

Cathie WoodJun 30, 2026
ARK Investment Management
Shares
1.3M
Value
$21.7M
% Portfolio
0.14%
Izzy EnglanderJun 30, 2026
Millennium Management
Shares
21.9K
Value
$369.9K
% Portfolio
0.00%

Previously held GENB

These investors reported GENB in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

Investor	Firm	Last reported shares	Value then	Last held
Paul Tudor Jones	Tudor Investment Corp	23.8K	$297.9K	Mar 31, 2026

Recent activity

Investor	Action	Δ %	Current value	Filing date
Izzy Englander	New	—	$4.7M	May 15, 2026
Izzy Englander	Sold	-100.00%	$0	Aug 14, 2026
Cathie Wood	New	—	$6.2M	May 12, 2026
Cathie Wood	Increased	157.74%	$21.7M	Aug 14, 2026
Paul Tudor Jones	New	—	$297.9K	May 15, 2026
Paul Tudor Jones	Sold	-100.00%	$0	Aug 14, 2026

Izzy Englander
New
$4.7MMay 15, 2026
Izzy Englander
Sold
$0(-100.00%)Aug 14, 2026
Cathie Wood
New
$6.2MMay 12, 2026
Cathie Wood
Increased
$21.7M(157.74%)Aug 14, 2026
Paul Tudor Jones
New
$297.9KMay 15, 2026
Paul Tudor Jones
Sold
$0(-100.00%)Aug 14, 2026

Frequently asked questions

How many institutional investors hold GENB?: 2 tracked institutional investors disclosed a position in GENB (GENERATE BIOMEDICINES INC) in their most recent 13F filing.
Who is the largest institutional holder of GENB?: Cathie Wood, ARK Investment Management, holds the largest disclosed position in GENB, valued at $22M.
Did institutional ownership of GENB increase or decrease?: Across recent 13F filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 2 fully exited GENB.
Where does this GENB ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.